Baird lowered the firm’s price target on Nurix Therapeutics to $24 from $31 and keeps an Outperform rating on the shares. The firm said the share’s recent pullback has dropped its enterprise value to about zero. They believe this leaves the stock at a favorable entry point, especially when considering that the company has three collaborations, and a history of these collaborations meaningfully attenuating cash burn.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NRIX:
- Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
- Nurix Therapeutics price target raised to $35 from $33 at H.C. Wainwright
- Cathie Wood’s ARK Investment bought 341.3K shares of Nurix Therapeutics today
- Nurix Therapeutics partners with Seagen to develop cancer therapeutics
- Nurix Therapeutics to Participate in Upcoming Investor Conferences